ATE231549T1 - Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung - Google Patents

Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung

Info

Publication number
ATE231549T1
ATE231549T1 AT97933740T AT97933740T ATE231549T1 AT E231549 T1 ATE231549 T1 AT E231549T1 AT 97933740 T AT97933740 T AT 97933740T AT 97933740 T AT97933740 T AT 97933740T AT E231549 T1 ATE231549 T1 AT E231549T1
Authority
AT
Austria
Prior art keywords
viruses
viral
recombining
aqueous suspension
medical use
Prior art date
Application number
AT97933740T
Other languages
German (de)
English (en)
Inventor
Claude Sene
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE231549T1 publication Critical patent/ATE231549T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT97933740T 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung ATE231549T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9608851A FR2751343B1 (fr) 1996-07-16 1996-07-16 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
PCT/FR1997/001308 WO1998002522A1 (fr) 1996-07-16 1997-07-15 Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament

Publications (1)

Publication Number Publication Date
ATE231549T1 true ATE231549T1 (de) 2003-02-15

Family

ID=9494078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933740T ATE231549T1 (de) 1996-07-16 1997-07-15 Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung

Country Status (11)

Country Link
US (2) US6451256B1 (enExample)
EP (1) EP0853660B1 (enExample)
JP (1) JP3681401B2 (enExample)
AT (1) ATE231549T1 (enExample)
AU (1) AU711409B2 (enExample)
CA (1) CA2232604C (enExample)
DE (1) DE69718612T2 (enExample)
DK (1) DK0853660T3 (enExample)
ES (1) ES2187798T3 (enExample)
FR (1) FR2751343B1 (enExample)
WO (1) WO1998002522A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
ES2185417T3 (es) * 1998-12-03 2003-04-16 Avigen Inc Excipientes para usar en formulaciones farmaceuticas de virus adeno-asociados, y formulaciones farmaceuticas producidas con ellos.
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
FR2791999B1 (fr) * 1999-04-09 2001-09-07 Aventis Pharma Sa Composition destinee a la conservation d'adenovirus recombinants infectieux
CA2364562A1 (fr) * 1999-04-09 2000-10-19 Aventis Pharma S.A. Composition destinee a la conservation d'adenovirus recombinants infectieux
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
WO2001085928A1 (en) * 2000-05-10 2001-11-15 Mitsubishi Pharma Corporation Method of preparing virus vector
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
JP2005515245A (ja) * 2002-01-18 2005-05-26 シエーリング アクチエンゲゼルシャフト アデノウィルスの安定化された配合物
KR100507794B1 (ko) * 2003-02-11 2005-08-17 한미약품 주식회사 고농도 레트로 바이러스 현탁액 제조 방법
US20070148765A1 (en) * 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
CN101343625A (zh) * 2004-02-23 2009-01-14 克鲁塞尔荷兰公司 病毒纯化方法
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
ES2317517T5 (es) * 2005-04-11 2016-01-21 Crucell Holland B.V. Purificación de virus usando ultrafiltración
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
AU2009319254B2 (en) 2008-11-03 2015-04-30 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
SG190418A1 (en) 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
ES2630012T3 (es) 2010-12-02 2017-08-17 Oncolytics Biotech Inc. Formulaciones virales liofilizadas
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
AU2013237424B2 (en) 2012-03-22 2017-07-06 Janssen Vaccines & Prevention B.V. Vaccine against RSV
CN104640564B (zh) 2012-07-10 2020-08-04 特兰斯吉恩股份有限公司 分枝杆菌抗原疫苗
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
BR112015031509B1 (pt) 2013-06-17 2023-05-09 Janssen Vaccines & Prevention B.V. Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende
RU2695462C2 (ru) 2014-01-09 2019-07-23 Трансген Са Гибридизация гетероолигомерных микобактериальных антигенов
US9721484B2 (en) 2014-06-23 2017-08-01 Humanetics Innovative Solutions, Inc. Shoulder kit assembly for crash test dummy
EP3169341B1 (en) 2014-07-16 2019-06-05 Transgene SA Oncolytic virus for expression of immune checkpoint modulators
US10008130B2 (en) 2014-09-17 2018-06-26 Humanetics Innovative Solutions, Inc. Omni-directional shoulder assembly for crash test dummy
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
BR112017027448A2 (pt) 2015-07-07 2018-09-04 Janssen Vaccines & Prevention Bv vacina contra rsv
WO2017005848A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
EA039095B1 (ru) 2016-04-05 2021-12-03 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-белки rsv до слияния
JP7046835B2 (ja) 2016-05-12 2022-04-04 ヤンセン ファッシンズ アンド プリベンション ベーフェー 強力でバランスのとれた双方向性プロモーター
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
JP6683847B2 (ja) 2016-06-20 2020-04-22 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 強力でバランスのとれた双方向性プロモーター
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
TW201825511A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
JP7110203B2 (ja) 2016-12-28 2022-08-01 トランジェーヌ 腫瘍溶解性ウイルスおよび治療用分子
BR112019015671A2 (pt) 2017-02-09 2020-04-14 Janssen Vaccines & Prevention Bv promotor potente e curto para expressão de genes heterológicos
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CN111163800A (zh) 2017-09-15 2020-05-15 扬森疫苗与预防公司 用于安全诱导针对rsv的免疫的方法
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3875119A4 (en) 2018-10-30 2022-08-31 The University of Tokyo ONCOLYTIC VIRUS FOR CANCER THERAPY
CR20210306A (es) 2018-11-13 2021-07-22 Janssen Vaccines & Prevention Bv Proteínas f de prefusión del vrs estabilizadas
EP4097122A4 (en) 2020-01-31 2024-07-17 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
CA3168761A1 (en) 2020-03-19 2021-09-23 Minna HASSINEN Temperature-responsive virus storage system
CN116322740A (zh) 2020-07-13 2023-06-23 特兰斯吉恩股份有限公司 免疫抑制的治疗
WO2022161502A1 (zh) 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用
KR20230147156A (ko) 2021-02-19 2023-10-20 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 rsv fb 항원
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
JP2025523573A (ja) 2022-07-01 2025-07-23 トランジェーヌ サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質
EP4573113A1 (en) 2022-08-18 2025-06-25 Transgene Chimeric poxviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
AU7971194A (en) * 1993-10-12 1995-05-04 Chiron Corporation Methods for preserving recombinant viruses
FR2711523B1 (fr) * 1993-10-26 1996-02-16 Transgene Sa Procédé de préparation d'un aérosol viral.
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5616487A (en) * 1994-09-15 1997-04-01 Aastrom Biosciences, Inc. Stabilized retrovirus compositions
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations

Also Published As

Publication number Publication date
WO1998002522A1 (fr) 1998-01-22
AU3698697A (en) 1998-02-09
DE69718612T2 (de) 2003-11-06
EP0853660B1 (fr) 2003-01-22
CA2232604C (fr) 2005-06-28
EP0853660A1 (fr) 1998-07-22
FR2751343A1 (fr) 1998-01-23
AU711409B2 (en) 1999-10-14
ES2187798T3 (es) 2003-06-16
CA2232604A1 (fr) 1998-01-22
US20030082206A1 (en) 2003-05-01
DE69718612D1 (de) 2003-02-27
JP2000500026A (ja) 2000-01-11
FR2751343B1 (fr) 1998-12-18
DK0853660T3 (da) 2003-05-05
JP3681401B2 (ja) 2005-08-10
US6451256B1 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
EA200400376A1 (ru) Пептиды, полученные из казеина, и их использование в терапии
DE69841982D1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
EP0431129A4 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
DE69429260D1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
ATE500808T1 (de) Onkolytische virustherapie
ES2114073T3 (es) Regeneracion del higado inducida por morfogenes.
FI961536A0 (fi) Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste
DE60009146D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
ATE189394T1 (de) Methode zur behandlung von viralen infektionen
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
ATE298582T1 (de) Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
ATE292177T1 (de) Gentherapy von lungenkrankheiten
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0853660

Country of ref document: EP